Probity Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.15M | Buy |
20,006
+1,467
| +8% | +$84.2K | 0.16% | 92 |
|
|
2026
Q1 | $1.12M | Buy |
18,539
+1,135
| +7% | +$66.2K | 0.18% | 93 |
|
|
2025
Q4 | $939K | Buy |
17,404
+10,381
| +148% | +$499K | 0.15% | 97 |
|
|
2025
Q3 | $317K | Buy |
+7,023
| New | +$328K | 0.05% | 194 |
|
|
2022
Q4 | $269K | Sell |
3,740
-560
| -13% | -$42.2K | 0.06% | 161 |
|
|
2022
Q3 | $306K | Sell |
4,300
-599
| -12% | -$43.5K | 0.08% | 147 |
|
|
2022
Q2 | $377K | Sell |
4,899
-404
| -8% | -$30.8K | 0.09% | 138 |
|
|
2022
Q1 | $387K | Sell |
5,303
-728
| -12% | -$48.9K | 0.08% | 147 |
|
|
2021
Q4 | $376K | Buy |
6,031
+711
| +13% | +$41.7K | 0.07% | 150 |
|
|
2021
Q3 | $315K | Buy |
5,320
+317
| +6% | +$20.9K | 0.07% | 172 |
|
|
2021
Q2 | $334K | Sell |
5,003
-216
| -4% | -$14.1K | 0.07% | 158 |
|
|
2021
Q1 | $329K | Buy |
+5,219
| New | +$325K | 0.07% | 153 |
|
|
2020
Q3 | $441K | Buy |
7,308
+357
| +5% | +$21.5K | 0.12% | 123 |
|
|
2020
Q2 | $409K | Buy |
6,951
+42
| +0.6% | +$2.51K | 0.13% | 123 |
|
|
2020
Q1 | $385K | Sell |
6,909
-200
| -3% | -$12.2K | 0.14% | 119 |
|
|
2019
Q4 | $456K | Buy |
7,109
+2,240
| +46% | +$128K | 0.14% | 127 |
|
|
2019
Q3 | $247K | Buy |
4,869
+171
| +4% | +$8.04K | 0.08% | 158 |
|
|
2019
Q2 | $213K | Sell |
4,698
-796
| -14% | -$37.1K | 0.07% | 164 |
|
|
2019
Q1 | $262K | Buy |
5,494
+706
| +15% | +$35.2K | 0.09% | 151 |
|
|
2018
Q4 | $249K | Sell |
4,788
-101
| -2% | -$5.43K | 0.09% | 147 |
|
|
2018
Q3 | $304K | Sell |
4,889
-237
| -5% | -$14.1K | 0.1% | 137 |
|
|
2018
Q2 | $284K | Buy |
5,126
+313
| +7% | +$16.9K | 0.1% | 137 |
|
|
2018
Q1 | $304K | Buy |
4,813
+91
| +2% | +$5.85K | 0.11% | 128 |
|
|
2017
Q4 | $289K | Sell |
4,722
-319
| -6% | -$20K | 0.1% | 132 |
|
|
2017
Q3 | $321K | Sell |
5,041
-12
| -0.2% | -$701 | 0.12% | 107 |
|
|
2017
Q2 | $282K | Buy |
5,053
+524
| +12% | +$28.5K | 0.11% | 117 |
|
|
2017
Q1 | $246K | Sell |
4,529
-1,751
| -28% | -$96K | 0.1% | 126 |
|
|
2016
Q4 | $367K | Buy |
6,280
+343
| +6% | +$18.8K | 0.15% | 99 |
|
|
2016
Q3 | $320K | Sell |
5,937
-638
| -10% | -$41K | 0.14% | 107 |
|
|
2016
Q2 | $484K | Buy |
+6,575
| New | +$465K | 0.22% | 88 |
|
Other funds holding BMY
Probity Advisors's BMY Position: Q2 2026 in Review
Probity Advisors increased its Bristol-Myers Squibb (BMY) stake by 7.9% in Q2 2026, buying an estimated $84.2K and bringing the position to 20,006 shares worth $1.15M. The position accounts for 0.16% of the portfolio, ranked #92.
Probity Advisors first reported a position in BMY in Q2 2016 and has held it in 30 quarters since. 2,526 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Probity Advisors held 20,006 shares of Bristol-Myers Squibb worth $1.15M as of Q2 2026.
- Probity Advisors bought 1,467 Bristol-Myers Squibb shares in Q2 2026, an estimated $84.2K.
- Bristol-Myers Squibb made up 0.16% of Probity Advisors's portfolio in Q2 2026, its #92 holding.
- Probity Advisors first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 30 quarters since.
- 2,526 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Probity Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.